ACI
CLDX icon

AMP Capital Investors’s Celldex Therapeutics CLDX Stock Holding History

AMP Capital Investors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,113
Closed -$177K – 1224
2016
Q3 		$177K Buy
+3,113
New +$194K ﹤0.01% 1187
2014
Q1 		– Sell
-2,312
Closed -$811K – 1208
2013
Q4 		$811K Buy
+2,312
New +$891K 0.01% 920

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AMP Capital Investors's CLDX Position: Q4 2016 in Review

AMP Capital Investors sold out of Celldex Therapeutics (CLDX) in Q4 2016, closing a stake of 3,113 shares — an estimated $177K sold.

AMP Capital Investors first reported a position in CLDX in Q4 2013 and held it in 2 quarters. The position peaked at $811K in Q4 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • AMP Capital Investors reported no remaining Celldex Therapeutics position as of Q4 2016 after selling out during the quarter.
  • AMP Capital Investors sold 3,113 Celldex Therapeutics shares in Q4 2016, an estimated $177K.
  • AMP Capital Investors first reported a position in Celldex Therapeutics in Q4 2013 and held it in 2 quarters.
  • AMP Capital Investors's Celldex Therapeutics position peaked at $811K in Q4 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on AMP Capital Investors's 13F filing for Q4 2016, filed 13 Feb 2017.